Xoma kept by Jefferies at hold

Xoma Ltd. was reiterated by Jefferies & Co. analyst Adam Walsh at a hold rating with a price target on the stock of $2 per share following its agreement with Cubist Pharmaceuticals Inc. to develop new manufacturing processes for two monoclonal antibodies that constitute HepeX-B for phase III trials. Xoma shares Tuesday were up $0.05, or 2.89%, at $1.78 on volume of 512,939 shares versus the three-month running average of 779,992 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.